NUMA1 and breast cancer: Six urine biomarkers approved by FDA have been applied for the diagnosis and monitoring of BCa, including NMP22 BC (nuclear matrix protein 22 ELISA test), NMP22 BladderChek, BTA Stat (qualitative test), BTA TRAK (quantitative test), UroVysion (FISH), and uCyt+/ImmunoCyt (fluorescent immunohistochemistry) (Table 1) [45,46].